BioRestorative Therapies, Inc. Common Stock (NV)
BRTXBioRestorative Therapies, Inc. (BRTX) is a biotechnology company focused on developing regenerative medicine solutions. It specializes in stem cell-based therapies aimed at treating various conditions, including pain management, sports medicine injuries, and degenerative diseases. The company's approach leverages its proprietary biologic products and advanced tissue engineering to promote healing and tissue regeneration.
Company News
BioRestorative Therapies announced completion of dosing in its Phase 2 clinical trial for BRTX-100, treating 99 patients with chronic lumbar disc disease. The randomized, double-blind, sham-controlled study has advanced to blinded follow-up with topline safety and efficacy data expected in Q2 2027. The company received FDA alignment on Phase 3 de...
BioRestorative Therapies presented preclinical data at ISCT 2026 demonstrating that extracellular vesicles derived from different mesenchymal stem cell sources exhibit distinct protein signatures and functional properties. The findings support development of targeted exosome-based formulations for regenerative and aesthetic applications, with imp...
BioRestorative Therapies will participate in the Be+Well Beauty and Wellness Show (March 8-10, 2026) to expand commercialization of its BioCosmeceutical platform. The company's commercial leadership team will engage with industry partners and distributors to discuss product adoption and deployment of regenerative skincare technologies. BioRestora...
BioRestorative Therapies, Inc. (NASDAQ:BRTX) announced the closing of a public offering of 14,285,715 shares and accompanying warrants at $0.35 per share, raising approximately $5.0 million in gross proceeds. The company plans to use the funds for clinical trials of BRTX-100 (a stem cell therapy for disc/spine disease), pre-clinical research on i...
BioRestorative Therapies (NASDAQ:BRTX) announced the pricing of a public offering of approximately 14.3 million shares and warrants at $0.35 per share, expected to raise $5.0 million in gross proceeds. The company plans to use the funds for clinical trials of BRTX-100, pre-clinical research for its ThermoStem Program, development of its biocosmec...
